CONNECT BIOPHARMA HOLDINGS L (CNTB) Stock Price & Overview
NASDAQ:CNTB • KYG235491019
The current stock price of CNTB is 2.48 USD. Today CNTB is up by 0.81%. In the past month the price increased by 7.83%. In the past year, price increased by 191.77%.
CNTB Key Statistics
- Market Cap
- 138.19M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.28
- Dividend Yield
- N/A
CNTB Stock Performance
CNTB Stock Chart
CNTB Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CNTB. When comparing the yearly performance of all stocks, CNTB is one of the better performing stocks in the market, outperforming 96.61% of all stocks.
CNTB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CNTB. The financial health of CNTB is average, but there are quite some concerns on its profitability.
CNTB Earnings
On November 12, 2025 CNTB reported an EPS of -0.31 and a revenue of 16.00K. The company beat EPS expectations (69.43% surprise).
CNTB Forecast & Estimates
11 analysts have analysed CNTB and the average price target is 8.06 USD. This implies a price increase of 224.92% is expected in the next year compared to the current price of 2.48.
For the next year, analysts expect an EPS growth of -212.62% and a revenue growth -99.83% for CNTB
CNTB Groups
Sector & Classification
CNTB Financial Highlights
Over the last trailing twelve months CNTB reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS increased by 74.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.2% | ||
| ROE | -28.22% | ||
| Debt/Equity | 0 |
CNTB Ownership
CNTB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.85 | 410.651B | ||
| AMGN | AMGEN INC | 16.4 | 197.945B | ||
| GILD | GILEAD SCIENCES INC | 16.14 | 180.072B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 116.919B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.36 | 80.868B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.87 | 42.343B | ||
| INSM | INSMED INC | N/A | 30.619B | ||
| NTRA | NATERA INC | N/A | 27.941B | ||
| BIIB | BIOGEN INC | 12.15 | 27.603B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.01 | 21.26B | ||
| MRNA | MODERNA INC | N/A | 21.03B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.746B | ||
| EXAS | EXACT SCIENCES CORP | 309.36 | 19.715B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CNTB
Company Profile
Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 62 full-time employees. The company went IPO on 2021-03-19. The firm is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The firm has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Company Info
CONNECT BIOPHARMA HOLDINGS L
3580 Carmel Mountain Road, Suite 200
San Diego CALIFORNIA 215400 US
CEO: William Pan
Employees: 62
Phone: 18587271040
CONNECT BIOPHARMA HOLDINGS L / CNTB FAQ
Can you describe the business of CONNECT BIOPHARMA HOLDINGS L?
Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 62 full-time employees. The company went IPO on 2021-03-19. The firm is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The firm has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
What is the current price of CNTB stock?
The current stock price of CNTB is 2.48 USD. The price increased by 0.81% in the last trading session.
Does CNTB stock pay dividends?
CNTB does not pay a dividend.
What is the ChartMill rating of CONNECT BIOPHARMA HOLDINGS L stock?
CNTB has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists CNTB stock?
CNTB stock is listed on the Nasdaq exchange.
What do analysts say about CONNECT BIOPHARMA HOLDINGS L (CNTB) stock?
11 analysts have analysed CNTB and the average price target is 8.06 USD. This implies a price increase of 224.92% is expected in the next year compared to the current price of 2.48.
Can you provide the short interest for CNTB stock?
The outstanding short interest for CONNECT BIOPHARMA HOLDINGS L (CNTB) is 0.88% of its float.